drugset / Trial / NCT04693507
Teverelix Evaluated in Advanced Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer
Timeline
- Start
- 2021-03-04
- Primary completion
- 2022-12-05
- Completion
- 2023-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | teverelix TFA | Unknown | 120 mg | Subcutaneous |
| Subject | teverelix TFA | Unknown | 180 mg | Subcutaneous |